ADVISORY, Feb. 12, 2014 (GLOBE NEWSWIRE) --
NephroGenex [NRX], a pharmaceutical company focusing on kidney disease, will visit the NASDAQ MarketSite in Times Square in celebration of its February 11 initial public offering (IPO) on The NASDAQ Stock Market.In honor of the occasion, Pierre Legault, Chief Executive Officer will ring the Opening Bell. Where: NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio When: Thursday, February 13, 2014 – 9:15 a.m. to 9:30 a.m. ET Contact: Susanna Mesa (646) 378-2933 firstname.lastname@example.org NASDAQ MarketSite: Christine Barna (646) 441-5310 Christine.Barna@nasdaqomx.com Feed Information: Fiber Line (Encompass Waterfront): 4463 Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK Social Media: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ. For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq. For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx. For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/. Webcast: A LiveStream of the NASDAQ Opening Bell will be available at: https://new.livestream.com/nasdaq/live Or http://www.nasdaq.com/about/marketsitetowervideo.asx. Photos: To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice. About NephroGenex [NRX]: NephroGenex (Nasdaq:NRX) is a clinical-stage pharmaceutical company focused on developing therapeutics to treat kidney diseases caused by pathogenic oxidative chemistries. Since our inception, we have collaborated with the world's leading experts and leveraged our knowledge of pathogenic oxidative chemistries to build a strong portfolio of intellectual property and to advance the development of our drug candidates. Our clinical product pipeline includes an oral formulation of Pyridorin, which is being developed as a chronic, therapeutic agent to slow the progression of diabetic nephropathy, as well as the application of an intravenous formulation of Pyridorin to treat specific types of acute kidney injury.